19230-58-1

Basic information

• Product Name: 2-broMo-5-Methylpyridine-1-o×ide
• Synonyms: 2-broMo-5-Methylpyridine-1-o×ide;2-Bromo-5-methylpyridin-1-ium-1-olate;Pyridine, 2-broMo-5-Methyl-, 1-oxide;2-bromo-5-methyl-1-oxidopyridin-1-ium
• CAS NO: 19230-58-1
• Molecular Formula: C₆H₆BrNO
• Molecular Weight: 188.02194
• Mol File: 19230-58-1.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-broMo-5-Methylpyridine-1-o×ide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-broMo-5-Methylpyridine-1-o×ide(19230-58-1)
• EPA Substance Registry System: 2-broMo-5-Methylpyridine-1-o×ide(19230-58-1)

Safety Data

• Hazardous Substances Data: 19230-58-1(Hazardous Substances Data)

Usage

General Description

2-Bromo-5-Methylpyridine-1-oxide is a synthetic organic compound. Its molecular formula is C6H6BrNO and its molecular weight is 188.02 g/mol. 2-broMo-5-Methylpyridine-1-o×ide has a pyridine ring which is a basic aromatic six-membered ring with five carbon atoms and one nitrogen atom. It is functionalized by a bromine atom on the second carbon and a methyl group on the fifth carbon, respectively. The nitrogen atom is oxidized, hence the name 1-oxide. It is mainly used as an intermediate for synthesizing other more complex compounds in the laboratory. Normally, it does not exist naturally and is synthesized in the laboratories for specific comprehensive studies.

Upstream product

• 3510-66-5 2-Bromo-5-methylpyridine 

Downstream Products

• 60323-98-0 2-bromo-5-methyl-4-nitropyridine N-oxide 
• 89466-16-0 6-bromo-3-methylpyridin-2-amine 
• 1350648-57-5 2-(3-fluoro-6-methylpyridin-2-yl)-5-methylpyridine 1-oxide 

Relevant articles and documents

HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce the excessive activation of complement.

MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS

This invention provides stable, highly crystalline forms of Complement factor D inhibitors Compound 1 and Compound 2 for advantageous therapeutic pharmaceutical efficacy and dosage form stability.

ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.